» Articles » PMID: 33154164

SUMOylation of the Ubiquitin Ligase IDOL Decreases LDL Receptor Levels and is Reversed by SENP1

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2020 Nov 6
PMID 33154164
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Inducible degrader of the low-density lipoprotein receptor (IDOL) is an E3 ubiquitin ligase mediating degradation of low-density lipoprotein (LDL) receptor (LDLR). IDOL also controls its own stability through autoubiquitination, primarily at lysine 293. Whether IDOL may undergo other forms of posttranslational modification is unknown. In this study, we show that IDOL can be modified by small ubiquitin-like modifier 1 at the K293 residue at least. The SUMOylation of IDOL counteracts its ubiquitination and augments IDOL protein levels. SUMOylation and the associated increase of IDOL protein are effectively reversed by SUMO-specific peptidase 1 (SENP1) in an activity-dependent manner. We further demonstrate that SENP1 affects LDLR protein levels by modulating IDOL. Overexpression of SENP1 increases LDLR protein levels and enhances LDL uptake in cultured cells. On the contrary, loss of SENP1 lowers LDLR levels in an IDOL-dependent manner and reduces LDL endocytosis. Collectively, our results reveal SUMOylation as a new regulatory posttranslational modification of IDOL and suggest that SENP1 positively regulates the LDLR pathway via deSUMOylation of IDOL and may therefore be exploited for the treatment of cardiovascular disease.

Citing Articles

Zebrafish mylipb attenuates antiviral innate immunity through two synergistic mechanisms targeting transcription factor irf3.

Li Z, Li J, Li Z, Song Y, Wang Y, Wang C PLoS Pathog. 2024; 20(5):e1012227.

PMID: 38739631 PMC: 11115282. DOI: 10.1371/journal.ppat.1012227.


Fatty acid-binding proteins 3, 7, and 8 bind cholesterol and facilitate its egress from lysosomes.

Fang X, Wei P, Zhao K, Sheng Z, Song B, Yin L J Cell Biol. 2024; 223(4).

PMID: 38429999 PMC: 10909654. DOI: 10.1083/jcb.202211062.


Targeting protein modifications in metabolic diseases: molecular mechanisms and targeted therapies.

Wu X, Xu M, Geng M, Chen S, Little P, Xu S Signal Transduct Target Ther. 2023; 8(1):220.

PMID: 37244925 PMC: 10224996. DOI: 10.1038/s41392-023-01439-y.


Lysosomal cholesterol accumulation is commonly found in most peroxisomal disorders and reversed by 2-hydroxypropyl-β-cyclodextrin.

Dong L, Xiao J, Liu S, Deng G, Liao Y, Chu B Sci China Life Sci. 2023; 66(8):1786-1799.

PMID: 36971991 DOI: 10.1007/s11427-022-2260-4.


Ubiquitin and its relatives as wizards of the endolysosomal system.

Berlin I, Sapmaz A, Stevenin V, Neefjes J J Cell Sci. 2023; 136(4).

PMID: 36825571 PMC: 10022685. DOI: 10.1242/jcs.260101.


References
1.
Rendtlew Danielsen J, Povlsen L, Villumsen B, Streicher W, Nilsson J, Wikstrom M . DNA damage-inducible SUMOylation of HERC2 promotes RNF8 binding via a novel SUMO-binding Zinc finger. J Cell Biol. 2012; 197(2):179-87. PMC: 3328386. DOI: 10.1083/jcb.201106152. View

2.
Kunz K, Piller T, Muller S . SUMO-specific proteases and isopeptidases of the SENP family at a glance. J Cell Sci. 2018; 131(6). DOI: 10.1242/jcs.211904. View

3.
Flotho A, Melchior F . Sumoylation: a regulatory protein modification in health and disease. Annu Rev Biochem. 2013; 82:357-85. DOI: 10.1146/annurev-biochem-061909-093311. View

4.
Zhou D, Udpa N, Ronen R, Stobdan T, Liang J, Appenzeller O . Whole-genome sequencing uncovers the genetic basis of chronic mountain sickness in Andean highlanders. Am J Hum Genet. 2013; 93(3):452-62. PMC: 3769925. DOI: 10.1016/j.ajhg.2013.07.011. View

5.
Nelson J, Sorrentino V, Avagliano Trezza R, Heride C, Urbe S, Distel B . The Deubiquitylase USP2 Regulates the LDLR Pathway by Counteracting the E3-Ubiquitin Ligase IDOL. Circ Res. 2015; 118(3):410-9. DOI: 10.1161/CIRCRESAHA.115.307298. View